NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
NOVARTIS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026
$150.20−0.42 (-0.28%)
Close on Oct 19, 2026
- Market cap
- $287.48B
- P/E (TTM)
- 21.0
- Dividend yield
- –
NOVARTIS AG revenue by segment
By business segment
| Operating income | Q2 23 | Q4 22 | Q2 22 | Q4 21 | Q2 21 | Q4 20 | Q2 20 | Q4 19 | Q2 19 | Q4 18 | Q2 18 | Q4 17 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicines | $3.00B | – | $2.21B | – | $3.18B | – | $2.03B | – | $2.56B | – | $2.25B | – | +35.9% |
| Sandoz | $212.00M | – | $357.00M | – | $462.00M | – | $321.00M | – | $282.00M | – | $328.00M | – | -40.6% |
| Corporate | -$291.00M | – | -$335.00M | – | -$160.00M | – | -$2.00M | – | -$183.00M | – | -$149.00M | – | -13.1% |
| Alcon [member] | – | – | – | – | – | – | – | – | – | – | $65.00M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Novartis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.